Gerard Francisco, MD
Physical Medicine & Rehabilitation · Houston, TXNPI 1992774707
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (56.9%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by Merz Pharmaceuticals, LLC at 40.4% of the total. Reporting peaked in 2019 at $98,877 and has fallen 76.5% since, to $23,274 in 2025. Among physical medicine & rehabilitation clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 276 payments — averaging $1317.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merz Pharmaceuticals, LLC$147K
- AbbVie$126K
- Merz North America, Inc.$46K
- Ipsen Innovation$14K
- Saol Therapeutics Inc.$12K
- Shionogi Inc$10K
- plus $9K from 6 others
Across 42 payments — averaging $4209.98 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merz Pharmaceuticals, LLC$83K
- AbbVie$50K
- Merz North America, Inc.$44K
What the payments were for
- Consulting fees$206,81557%
- Speaking & faculty fees$35,02710%
- Travel & lodging$114,16031%
- Food & beverage$7,5912%
- Education$210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merz Pharmaceuticals, LLC | 125 | $146,811 |
| AbbVie(2 entities) | 77 | $126,022 |
| Merz North America, Inc. | 41 | $45,880 |
| Ipsen Innovation | 3 | $14,276 |
| Saol Therapeutics Inc. | 4 | $12,045 |
| Shionogi Inc | 13 | $10,046 |
| Ipsen Biopharm Limited | 1 | $3,311 |
| Microtransponder, Inc. | 4 | $2,885 |
| Ipsen Pharma SAS | 1 | $1,775 |
| Ipsen Biopharmaceuticals, Inc | 3 | $299 |
| Pacira Pharmaceuticals Incorporated | 2 | $226 |
| Piramal Critical Care | 2 | $39 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$363,614 in reported general payments places this provider in the 95th percentile of 651 physical medicine & rehabilitation providers in Texas.
See all physical medicine & rehabilitation providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Baclofen | 15 | $808 |
| AmantadineAmantadine Hcl | 13 | $410 |
Paid to pharmacies, not to this prescriber.
Other physical medicine & rehabilitation in Houston
- Suzanne ManziHouston$143K
- Cindy IvanhoeHouston$111K
- Sheng LiHouston$44K
- Purvi DesaiHouston$20K
- Jenny LaiHouston$16K
- Tram PhamHouston$8K
- Marie FrandoHouston$7K
- Bo SongHouston$6K
- Jason HuaHouston$6K
- Teresa KaldisHouston$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.